← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
51	ADAP 51 DELISTED Adaptimmune Therapeutics ADAP	40	-6	-13%	$121M
52	52 Cellectis CLLS $111M	37	-2	-5%	$96.1M
53	53 Fate Therapeutics FATE $231M	37	-3	-8%	$57.9M
54	54 Fulgent Genetics FLGT $587M	37	+22	+147%	$35.5M
55	55 CareDx CDNA $3.45B	31	+6	+24%	$20.9M
56	56 Opus Genetics IRD $337M	31	-2	-6%	$3.2M
57	57 Pluri PLUR $11.9M	31	-6	-16%	$3.71M
58	58 DELISTED BRAINSTORM CELL THERAPUTC BCLI	27	+3	+13%	$3.94M
59	59 DELISTED Carisma Therapeutics CARM	27	-2	-7%	$4.82M
60	60 CRISPR Therapeutics CRSP $4.98B	26	+26	–	$198M
61	ONCS 61 DELISTED OncoSec Medical Incorporated ONCS	26	+5	+24%	$2.71M
62	62 Imunon IMNN $5.95M	23	-3	-12%	$1.51M
63	63 Ocugen OCGN $276M	23	+2	+10%	$19.9M
64	64 ProQR Therapeutics PRQR $205M	23	-2	-8%	$43.6M
65	65 Capricor Therapeutics CAPR $423M	20	-2	-9%	$2.57M
66	66 DELISTED BioLife Solutions BLFS	19	+2	+12%	$431K
67	67 Qiagen QGEN $9.53B	18	+16	+800%	$722M
68	68 Mesoblast MESO $1.81B	16	-1	-6%	$13.1M
69	69 Enlivex Ltd ENLV $4.46M	13	-1	-7%	$1.4M
70	HTGM 70 DELISTED HTG Molecular Diagnostics, Inc. Common Stock HTGM	13	-9	-41%	$6.47M
71	PTE 71 DELISTED PolarityTE, Inc. Common Stock PTE	12	+3	+33%	$606K
72	72 Eterna Therapeutics ERNA $2.53M	8	+1	+14%	$4.46M
73	CYAD 73 DELISTED Celyad Oncology SA American Depositary Shares CYAD	6	-1	-14%	$6.8M
74	74 ARK Genomic Revolution ETF ARKG $2.09B	5	0	0%	$586K
75	75 Marker Therapeutics MRKR $15.3M	5	+5	–	$119K